Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Bristol-Myers Squibb ( (BMY) ) is now available.
On January 12, 2026, Bristol Myers Squibb used its appearance at the 44th Annual J.P. Morgan Healthcare Conference to highlight that it has been “built for growth,” emphasizing a 17% year-on-year increase in Growth Portfolio sales for the first nine months of 2025, four assets already annualizing above $1 billion in revenue, stronger operating cash flow, and productivity initiatives including scaled use of AI to generate cost savings for reinvestment. The company detailed a broad late-stage pipeline with multiple potential multi-billion-dollar assets across cardiovascular, immunology, oncology and neuroscience, outlined significant registrational and pivotal trial readouts expected from 2026 through 2028, and projected more than 10 potential new product launches by 2030, underscoring a strategic focus on sustaining industry-leading long-term growth and reinforcing its competitive position in key therapeutic areas.
The most recent analyst rating on (BMY) stock is a Hold with a $47.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.
Spark’s Take on BMY Stock
According to Spark, TipRanks’ AI Analyst, BMY is a Outperform.
Bristol-Myers Squibb’s strong earnings call and technical indicators are the most significant factors driving the score. The company’s robust growth portfolio and strategic initiatives, coupled with fair valuation and solid financial performance, position it well for future growth. However, high debt levels and challenges in new product adoption present risks that need to be managed.
To see Spark’s full report on BMY stock, click here.
More about Bristol-Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing and commercializing innovative medicines, with a portfolio and pipeline concentrated in oncology, cardiovascular disease, immunology and neuroscience, targeting large patient populations and serious, often life-threatening conditions worldwide.
Average Trading Volume: 15,651,138
Technical Sentiment Signal: Strong Buy
Current Market Cap: $113.8B
For a thorough assessment of BMY stock, go to TipRanks’ Stock Analysis page.